



Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.: OC01000KQ

APPLICATION NO.: 09/904,263

APPLICANT:
Mary Ellen Rybak, et al.

FILING DATE:
07/12/2001

GROUP:
1642

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE IF APPROPRIATE |
|-------------------|-----------------|------|------|-------|-----------|----------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION YES | NO |
|--|-----------------|------|---------|-------|-----------|-----------------|----|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|-----|----|--|
| ARH | AA | Bruno, René, et al., "Population Pharmacokinetics/Pharmacodynamics of Docetaxel in Phase II Studies in Patients with Cancer," <i>Journal of Clinical Oncology</i> 16(1):187-96 (1998) |
| ARH | AB | Calvert, A.H., et al., "Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function," <i>Journal of Clinical Oncology</i> 7(11):1748-56 (1989) |
| ARH | AC | Eisenhauer, Elizabeth A., et al., "The Taxoids, Comparative Clinical Pharmacology and Therapeutic Potential," <i>Drugs</i> 55(1):5-30 (1998) |
| ARH | AD | Eksborg, Steffan, et al., "Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite-a comparison of bolus versus 2 h infusion during a 3 day course," <i>Anti-Cancer Drugs</i> 8:42-7 (1997) |
| ARH | AE | Forastiere, Arlene A., et al., "Pharmacokinetic and Toxicity Evaluation of Five-Day Continuous Infusion versus Intermittent Bolus <i>cis</i> -Diamminedichloroplatinum(II) in Head and Neck Cancer Patients," <i>Cancer Research</i> 48:3869-3874 (1988) |
| ARH | AF | Gandhi, Varsha, et al., "Compound GW506U78 in Refractory Hematologic Malignancies: Relationship Between Cellular Pharmacokinetics and Clinical Response," <i>Journal of Clinical Oncology</i> 16(11):3607-15 (1998) |
| ARH | AG | Rodman, John H., et al., "Clinical Pharmacodynamics of Continuous Infusion Teniposide: Systemic Exposure as a Determinant of Response in a Phase I Trial," <i>Journal of Clinical Oncology</i> 5(7):1007-1014 (1987) |
| ARH | AH | Shalinsky, David R., et al., "Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations," <i>Investigational New Drugs</i> 16:303-13 (1999) |
| ARH | AI | Takitani, Kimitaka, et al., "4-Oxo Retinoic Acid for Refractory Acute Promyelocytic Leukemia in Children with All-Trans Retinoic Acid Therapy," <i>J. Nutr. Sci. Vitaminol.</i> 41:493-98 (1995) |

EXAMINER

Anne L. McLean

DATE CONSIDERED

6/25/2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.